Skip to search formSkip to main contentSkip to account menu

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Known as: Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Human Papillomavirus Quadrivalent (types 6, 11, 16 and 18) Vaccine Recombinant, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine 
A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (1)

Gardasil
In BloodNCIt Antineoplastic Agent TerminologyProcess of secretionV501

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
Highly Cited
2017
Highly Cited
2017
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)
BackgroundSafety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine were evaluated in HIV-positive… 
Highly Cited
2015
Highly Cited
2015
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Highly Cited
2014
Highly Cited
2014
Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.
BACKGROUND In clinical trials, vaccines against human papillomavirus (HPV) have been highly effective against HPV16- or HPV18… 
Review
2014
Review
2014
Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis
The aim of the study was to assess the clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with… 
Highly Cited
2013
Highly Cited
2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
IMPORTANCE Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer is impeded by cost. A 2-dose schedule for… 
Highly Cited
2012
Highly Cited
2012
Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study
Objectives To evaluate the immunogenicity and safety of GARDASIL, a quadrivalent human papillomavirus (HPV) vaccine, in patients… 
Highly Cited
2012
Highly Cited
2012
Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination.
Review
2009
Review
2009
HPV & HPV vaccination: issues in developing countries.
Cervical cancer is the second-most common cancer in women worldwide causing most cancer related deaths in women in developing… 
Highly Cited
2007
Highly Cited
2007
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)